Olmesartan Medoxomil CAS 144689-63-4 Puritas >99.5% (HPLC) API Factory
Ruifu Chemical Supple Olmesartan Medoxomil media cum High Quality:
4,5-Dimethyl-1,3-Dioxol-2-Unum (DMDO) CAS 37830-90-3
4-Chloromethyl-5-Methyl-1,3-Dioxol-2-Unum (DMDO-Cl) CAS 80841-78-7
Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylatus CAS 144689-93-0
Diethyl 2-propyl-1H-Imidazole-4,5-Dicarboxylatus CAS 144689-94-1
Trityl Olmesartan Ethyl Ester CAS 144690-33-5
Trityl Olmesartan Acid CAS 761404-85-7
N2-Trityl Olmesartan Acid CAS 752179-89-8
Trityl Olmesartan Medoxomil CAS 144690-92-6
Olmesartan Medoxomil CAS 144689-63-4
Nomen chemicum | Olmesartan Medoxomil |
Synonyma | 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H- imidazole-5-carboxylicum Acidum (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester;CS-866 |
CAS Number | 144689-63-4 |
CATTUS Number | RF-PI1730 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C29H30N6O6 |
M. Pondus | 558.60 |
Liquescens punctum | 180 (dec.) |
Aqua Solubility | Insolubilis in aqua;Leviter solutum in DMSO |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | White ad fere album Cyrstalline pulveris |
Lepidium sativum | IR, HPLC, UV: Oportet Reference Latin |
Puritas / Analysis Methodus | >99.5% (HPLC in Anhydrous et Solvent-Free Basis) |
Damnum in Siccatio | <0.50% |
Residere in Ignition | <0.10% |
Substantiae cognatae | |
Olmesartan RRT 0.2 | <0.50% |
Olmesartan Medoxoil Related Compone A. RRT 0.7 | <0.20% |
Olefinic Impuritas RRT 1.6 | <0.50% |
N-Alkyl Impuritas RRT 3.4 | <0.10% |
Alia immunditia | <0.10% |
Totalis immunditias | <0.50% |
Metalla gravia (ut Pb) | <10ppm |
pH Solutio (%, W/V) | 4.5 ad 6.5 |
Test Standard | Enterprise Latin;USP Standard |
Consuetudinem | API |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
Olmesartan Medoxomil (CS-866) (CAS: 144689-63-4) potens et selectivum angiotensin II typus 1 (AT(1)) receptor adversarius cum IC50 ex 66.2 μM, adhibitus in curatione pressurae sanguinis altae.Usus est ut anti-hypertensive.Olmesartan opera ligamen angiotensin II ad AT1 receptores in musculo vasculari obstruendo.Olmesartan obstringendo obligationem potius quam synthesim angiotensin II, vetat opiniones regulatorias negativas de secretione renini.Olmesartan Medoxomil est pro-medicamentum quod de-estificatum ad metabolitam activam, olmesartanam.Olmesartan Medoxomil in US Benicar deductum est, viva voce curatio hypertensionis administratum.